Nonsteroidal anti-inflammatory drugs in viral infections disease, specially COVID-19

Chamkouri, Narges; Absalan, Forouzan; Koolivand, Zahra; Yousefi, Mahsa

Nonsteroidal anti-inflammatory drugs in viral infections disease, specially COVID-19

Authors

Medical Faculty, Abadan University of Medical Sciences, Abadan, Iran

Abstract

During the current SARS-CoV-2 (COVID-19) pandemic, some reports were presented based on those nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. According to this, we aimed to collate information available in published articles to identify any evidence behind these statements with the aim of helping clinicians on how best to treat patients. We could not find published conclusive evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilized in the early acute phase of infection, however, conflicting WHO (World Health Organization) evidence surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients. However, the availability of reliable information for clinicians and patients is paramount.

Keywords

References

1.	Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433.
2.	Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19: Towards controlling of a pandemic. Lancet 2020;395:1015-8.
3.	Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020;91:264-6.
4.	McKeever A. Here's what coronavirus does to the body. In: National Geographic. United States. National Geographic Partners, LLC; 2020. Available from: http://www.nationalgeographic.com/science. [Lat accessed on 2021 Mar 25].
5.	Jarcho JA, Ingelfinger JR, Hamel MB, D'Agostino RB Sr., Harrington DP. Inhibitors of the renin-angiotensin-aldosterone system and COVID-19. Mass Med Soc 2020;382:2462-4.
6.	Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909.
7.	Lanas A, Chan FK. Peptic ulcer disease. Lancet 2017;390:613-24.
8.	Buer JK. Origins and impact of the term 'NSAID'. Inflammopharmacology 2014;22:263-7.
9.	Day RO, Graham GG. The vascular effects of COX-2 selective inhibitors. Aust Prescr 2004;27:142-5.
10.	Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1-15.
11.	Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003;63:525-34.
12.	Warden SJ. Prophylactic use of NSAIDs by athletes: A risk/benefit assessment. Phys Sportsmed 2010;38:132-8.
13.	Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008;22:383-90.
14.	Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, et al. Hypertension and renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. MedRxiv 2020;382:1653-9.
15.	Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med 2020;382:1653-9.
16.	Page CP, Curtis MJ, Sutter M, Walker M, Hoffman B. Farmacología Integrada (in Spanish). España: Elsevier; 1998.
17.	Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565-74.
18.	Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92:401-2.
19.	Mocarski ES Jr. Virus self-improvement through inflammation: No pain, no gain. Proc Natl Acad Sci U S A 2002;99:3362-4.
20.	Julkunen I, Melén K, Nyqvist M, Pirhonen J, Sareneva T, Matikainen S. Inflammatory responses in influenza A virus infection. Vaccine 2000;19 Suppl 1:S32-7.
21.	Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am J Health Syst Pharm 2006;63:1837-51.
22.	Dauletbaev N, Lam J, Eklove D, Iskandar M, Lands LC. Ibuprofen modulates NF-κB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. Respiration 2010;79:234-2.
23.	Rocca J, Manin S, Hulin A, Aissat A, Verbecq-Morlot W, Prulière-Escabasse V, et al. New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis. Br J Pharm 2016;173:1728-41.
24.	Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999;5:698-701.
25.	Inaoka M, Kimishima M, Takahashi R, Shiohara T. Non-steroidal anti-inflammatory drugs selectively inhibit cytokine production by NK cells and γδ T cells. Exp Dermatol 2006;15:981-90.
26.	FitzGerald GA. Misguided drug advice for COVID-19. Science 2020;367:1434.
27.	Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: Lessons from other pathogenic viruses. Emerg Microbes Infect 2020;9:558-70.
28.	Kirkby NS, Zaiss AK, Wright WR, Jiao J, Chan MV, Warner TD, et al. Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies. Biochem Biophys Res Commun 2013;438:249-56.
29.	Fitzgerald DW, Bezak K, Ocheretina O, Riviere C, Wright TC, Milne GL, et al. The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) 2012;5:34-40.
30.	Carey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC, Germolec DR. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol 2005;175:6878-84.
31.	Capuano A, Scavone C, Racagni G, Scaglione F; Italian Society of Pharmacology. NSAIDs in patients with viral infections, including COVID-19: Victims or perpetrators? Pharmacol Res 2020;157:104849.
32.	Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
33.	Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020;133:1025-31.
34.	Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.
35.	Davis A, Robson J. The dangers of NSAIDs: Look both ways. Br J Gen Pract 2016;66:172-3.
36.	European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 [online]. 2020. Available: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal anti-inflammatories-covid-19. [Last accessed on 2020 Mar 24].
37.	Torjesen I. COVID-19: Ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ 2020;369:m1555.
38.	Dowling C. Is there a benefit in using non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) in the prevention of cytokine storms in the treatment against an individual who is infected with COVID-19. J Med Adv Clin Case Rep 2020;177:4899-920.
39.	Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 2016;13:3-10.
40.	Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94:e00127-20.
41.	Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 2015;131:97-106.
42.	Langhendries JP, Allegaert K, Van Den Anker JN, Veyckemans F, Smets F. Possible effects of repeated exposure to ibuprofen and acetaminophen on the intestinal immune response in young infants. Med Hypotheses 2016;87:90-6.
43.	Day M. COVID-19: European drugs agency to review safety of ibuprofen. BMJ 2020;368:m1168.
44.	Kaplan HB, Edelson HS, Korchak HM, Given WP, Abramson S, Weissmann G. Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo. Biochem Pharmacol 1984;33:371-8.
45.	Perianin A, Roch-Arveiller M, Giroud JP, Hakim J. In vivo interaction of nonsteroidal anti-inflammatory drugs on the locomotion of neutrophils elicited by acute non-specific inflammations in the rat – Effect of indomethacin, ibuprofen and flurbiprofen. Biochem Pharmacol 1984;33:2239-43.
46.	Ghosh R, Alajbegovic A, Gomes AV. NSAIDs and cardiovascular diseases: Role of reactive oxygen species. Oxid Med Cell Longev 2015;2015:536962.
47.	D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the "cytokine storm" for therapeutic benefit. Clin Vaccine Immunol 2013;20:319-27.
48.	Hanson A, Haddad LM. Nursing Rights of Medication Administration. StatPearls Publishing, Treasure Island (FL). Campbell University School of Osteopathic Medicine. East Tennessee State University. Copyright © 2022, StatPearls Publishing LLC.
49.	Fang L, Karakiulakis G, Roth M. Antihypertensive drugs and risk of COVID-19? – Authors' reply. Lancet Respir Med 2020;8:e32-3.
50.	Kelleni MT. ACEIs, ARBs, ibuprofen originally linked to COVID-19: The other side of the mirror. Inflammopharmacology 2020;28:1477-80.
51.	Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. MedRxiv 2020.
52.	Moore N, Carleton B, Blin P, Bosco-Levy P, Droz C. Does ibuprofen worsen COVID-19? Drug Saf 2020;43:611-4.
53.	Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117477.
54.	Kotsiou OS, Zarogiannis SG, Gourgoulianis KI. Prehospital NSAIDs use prolong hospitalization in patients with pleuro-pulmonary infection. Respir Med 2017;123:28-33.
55.	Capuano A, Scaglione F, Berrino L, Del Re M, Bernardini R, Chiamulera C, et al. Official statement of the section of clinical pharmacology of italian society of pharmacology on non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections. Pharm Adv 2020;177:4899-920.
56.	Xu T, Gao X, Wu Z, Selinger DW, Zhou Z. Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo. BioRxiv 2020.
57.	Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect 2020;26:1259.e5-7.
58.	Emeka PM, Morsy MA, Alhaider IA, Chohan MS. Protective effect of caffeic acid phenethyl ester against acute and subchronic mice cardiotoxicity induced by cyclophosphamide alone or plus naproxen. Pharmacogn Mag 2020;16:585.
59.	Kodidala SR, Sorout J, Jayachandra S, Narapogu V. Indomethacin & SARS-CoV-2: Prospects for clinical management of the inflammatory state. RUDN J Med 2021;25:25-30.
60.	Huo C, Xiao J, Xiao K, Zou S, Wang M, Qi P, et al. Pre-treatment with zirconia nanoparticles reduces inflammation induced by the pathogenic H5N1 influenza virus. Int J Nanomedicine 2020;15:661-74.
61.	Zhao D, Zhang S, Igawa T, Frishman W. Use of nonsteroidal anti-inflammatory drugs for COVID-19 infection: Adjunct therapy? Cardiol Rev 2020;28:303-7.

Advanced Biomedical Research